| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Genetics Division, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom
The Chinese hamster ovary cell line xrs-1 is hypersensitive to 
-radiation. This sensitivity has been attributed to an inability of this cell line to efficiently repair -ray induced double-strand breaks (DSBs). We have recently reported that xrs-1 is also sensitive to topoisomerase II inhibitors that stabilize the cleavable complex. In this study, we have investigated the basis of this sensitivity by monitoring cleavable complex formation and loss in xrs-1 and its parent CHO-KI following treatment with the topoisomerase II inhibitors etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide. Our studies indicate that xrs and CHO-KI cells accumulate drug-induced cleavable complexes at equal rates and to an equal extent. However, studies on the loss of cleavable complexes after drug removal suggest that protein-free DSBs arise in cells treated with topoisomerase II inhibitors. Furthermore, a larger number of these DSBs persist in repair-deficient xrs cells than in repair-proficient Chinese hamster ovary-KI cells. The persistence of DSBs appears to account for the cytotoxic effects of topoisomerase II inhibitors that stabilize the cleavable complex. These results suggest that the xrs repair pathway is required for efficient removal of potentially cytotoxic DSBs that arise in cells treated with topoisomerase II inhibitors.
1 To whom requests for reprints should be addressed.
Received 3/ 9/90. Accepted 6/13/90.
This article has been cited by other articles:
|
|
 |
|
  X. Liang, M. T. Pickering, N.-H. Cho, H. Chang, M. R. Volkert, T. F. Kowalik, and J. U. Jung Deregulation of DNA Damage Signal Transduction by Herpesvirus Latency-Associated M2. J. Virol., June 1, 2006; 80(12): 5862 - 5874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhao, H. D. Thomas, M. A. Batey, I. G. Cowell, C. J. Richardson, R. J. Griffin, A. H. Calvert, D. R. Newell, G. C.M. Smith, and N. J. Curtin Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441. Cancer Res., May 15, 2006; 66(10): 5354 - 5362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. S. Ayene, L. P. Ford, and C. J. Koch Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and {gamma} radiation Mol. Cancer Ther., April 1, 2005; 4(4): 529 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. U. Barthelmes, M. Habermeyer, M. O. Christensen, C. Mielke, H. Interthal, J. J. Pouliot, F. Boege, and D. Marko TDP1 Overexpression in Human Cells Counteracts DNA Damage Mediated by Topoisomerases I and II J. Biol. Chem., December 31, 2004; 279(53): 55618 - 55625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Willmore, S. de Caux, N. J. Sunter, M. J. Tilby, G. H. Jackson, C. A. Austin, and B. W. Durkacz A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia Blood, June 15, 2004; 103(12): 4659 - 4665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Hong and K. N. Kreuzer Endonuclease cleavage of blocked replication forks: An indirect pathway of DNA damage from antitumor drug-topoisomerase complexes PNAS, April 29, 2003; 100(9): 5046 - 5051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Wilson, M. A. Johnson, A. P. Stuckert, K. L. Trueman, S. May, P. E. Bryant, R. E. Meyn, A. D. D'Andrea, and N. J. Jones The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange Carcinogenesis, December 1, 2001; 22(12): 1939 - 1946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Stohr and K. N. Kreuzer Repair of Topoisomerase-Mediated DNA Damage in Bacteriophage T4 Genetics, May 1, 2001; 158(1): 19 - 28. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Willmore, A. J. Frank, K. Padget, M. J. Tilby, and C. A. Austin Etoposide Targets Topoisomerase IIalpha and IIbeta in Leukemic Cells: Isoform-Specific Cleavable Complexes Visualized and Quantified In Situ by a Novel Immunofluorescence Technique Mol. Pharmacol., July 1, 1998; 54(1): 78 - 85. [Abstract] [Full Text]
|
|
|
|
|
|
S. J. Froelich-Ammon, D. A. Burden, M. W. Patchan, S. H. Elsea, R. B. Thompson, and N. Osheroff Increased Drug Affinity as the Mechanistic Basis for Drug Hypersensitivity of a Mutant Type II Topoisomerase J. Biol. Chem., November 24, 1995; 270(47): 28018 - 28021. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
